Why should pharmacological trials in schizophrenia employ functional magnetic resonance imaging (fMRI)?

Evangelos Papanastasiou; Sukhwinder S. Shergill

doi:10.1177/02698811211000773

Why should pharmacological trials in schizophrenia employ functional magnetic resonance imaging (fMRI)?

Evangelos Papanastasiou^*, Sukhwinder S. Shergill

^*Corresponding author for this work

Research output: Contribution to journal › Letter › peer-review

3 Citations (Scopus)

Original language	English
Pages (from-to)	1158-1160
Number of pages	3
Journal	Journal of Psychopharmacology
Volume	35
Issue number	9
DOIs	https://doi.org/10.1177/02698811211000773
Publication status	Published - Sept 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1177/02698811211000773

Cite this

@article{b94d14b23d3a45c4a5f8e412a115b9fe,

title = "Why should pharmacological trials in schizophrenia employ functional magnetic resonance imaging (fMRI)?",

author = "Evangelos Papanastasiou and Shergill, {Sukhwinder S.}",

note = "Funding Information: The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: SS is supported by a European Research Council (ERC) Consolidator Award and by the National Institute for Health Research (NIHR) South London and Maudsley Biomedical Research Centre (BRC). Copyright: Copyright 2021 Elsevier B.V., All rights reserved.",

year = "2021",

month = sep,

doi = "10.1177/02698811211000773",

language = "English",

volume = "35",

pages = "1158--1160",

journal = "Journal of Psychopharmacology",

issn = "0269-8811",